Agilent Technologies Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everybody. My name is Luke Sergott. I cover life sciences tools and diagnostics at Barclays. It's my pleasure to introduce Bob McMahon from Agilent. We're just going to kind of dive in here, but if you want to give a couple of points and then we can go into the questions.
Yes, sure. So it's great to see people in person after a long respite. So -- but -- the good news is Agilent continues to have a very strong business. And we just finished our first quarter with strong double-digit growth. And actually, our orders grew faster than our revenues. And so we see continued business momentum and are excited about our prospects going forward. I'm sure we'll talk about some of the growth drivers that we have as we continue to transition our business to more of those faster-growing areas. And so let's jump right in.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |